Subchronic effects of the GABA-agonist lorazepam and the 5-HT2A/2C antagonist ritanserin on driving performance, slow wave sleep and daytime sleepiness in healthy volunteers

Psychopharmacology

Volumn 154, Issue 2, 2001, Pages 189-197

  Van Laar, Margriet ^a   Volkerts, E ^a   Verbaten, M ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Daytime sleepiness; Driving performance; GABA; Lorazepam; Ritanserin; Serotonin; Slow wave sleep

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; LORAZEPAM; PLACEBO; RITANSERIN; SEROTONIN; SEROTONIN 2A ANTAGONIST; SEROTONIN 2C ANTAGONIST;

ADULT; ARTICLE; CAR DRIVING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRIVING ABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG SAFETY; ELECTROENCEPHALOGRAM; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PSYCHOMOTOR PERFORMANCE; SLOW WAVE SLEEP; SOMNOLENCE; VOLUNTEER;

ADULT; ANALYSIS OF VARIANCE; AUTOMOBILE DRIVING; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; GABA MODULATORS; HUMANS; LORAZEPAM; MALE; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTOR, SEROTONIN, 5-HT2C; RECEPTORS, SEROTONIN; RITANSERIN; SEROTONIN ANTAGONISTS; SLEEP; SLEEP STAGES;

EID: 0035114901     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130000633     Document Type: Article

References (68)

1. Sleep is for tissue restoration
2. Effects of repeated ritanserin on middle-aged poor sleepers
3. Development of tolerance and cross-tolerance to the psychomotor actions of lorazepam and diazepam in man
4. Ritanserin, imipramine, and placebo in the treatment of dysthymic disorder
5. Association of road-traffic accidents with benzodiazepine use
6. Safety evaluation of ritanserin - An investigational serotonin antagonist
7. Einige praktische konsequenzen aus der aktivierungstheorie
8. 2 receptor antagonism in dysthymic disorder: A double-blind placebo-controlled study with ritanserin
9. Alerting effects of methylphenidate under basal and sleep-deprived conditions
10. Biological basis of generalised anxiety disorder
11. Guidelines for the multiple sleep latency test (MSLT): A standard measure of sleepiness
12. The influence of ritanserin, a serotonin antagonist, in anxiety disorders: A double-blind placebo-controlled study versus lorazepam
13. 2 receptor sensitivity in generalised anxiety disorder: A pilot study with ritanserin
14. Comparative study of the psychomotor and anti-stress effects of ritanserin, alprazolam and diazepam in healthy subjects: Some trait anxiety-independent responses
15. The efficacy of drug treatments for dysthymia: A systematic review and meta-analysis
16. Acute effects of triazolam in women: Relationships with progesterone, estradiol and allopregnanolone
17. Serotonergic mechanisms in anxiety
18. Single-dose ritanserin and alcohol in healthy volunteers: A placebo-controlled trial
19. Effects of acute and subchronic administration of ritanserin on the social behaviour of mice
20. Recent developments in 5HT-related pharmacology of animal models of anxiety
21. Ritanserin and flupenthixol in dysthymic disorder
22. Serotonergic systems
23. Intravenous flumazenil following acute and repeated exposure to lorazepam in healthy volunteers: Antagonism and precipitated withdrawal
24. Effects of lorazepam on the automatic online evaluation of sleep EEG data in healthy volunteers
25. A dose-response study examining the effects of ritanserin on human slow wave sleep
26. Does ritanserin, a potent serotonin-S2 antagonist, restore energetic functions during the night?
27. Sleepiness in different situations measured by the Epworth Sleepiness Scale
28. Subjective and objective measures of sleepiness: Effect of benzodiazepine and caffeine on their relationship
29. 2) mediation of anxiety-therapeutic effects of serazepine in generalized anxiety disorder
30. Sleep latency measures of caffeine effects during sleep deprivation
31. Benzodiazepines and vigilance performance: A review
32. Future directions in anxiolytic pharmacotherapy
33. 2 receptor blocker, as add-on treatment in narcolepsy
34. New developments in the pharmacological treatment of anxiety
35. Evaluation of daytime sleepiness
36. Risk of traffic accident injury after a prescription for a benzodiazepine
37. Benzodiazepine-related traffic accidents in young and elderly drivers
38. Performance testing as a part of drug registration
39. Anxiolytics' effects on the actual driving performance of patients and healthy volunteers in a standardized test. An integration of three studies
40. Venlafaxine's effects on healthy volunteers' driving, psychomotor, and vigilance performance during 15-day fixed and incremental dosing regimens
41. Sleep as restorative process: Human clues
42. Effects of ritanserin on sleep disturbances of dysthymic patients
43. Gender-related differences in diazepam effects on performance
44. Electrophysiological assessment (The Multiple Sleep Latency Test) of the biphasic effects of ethanol in humans
45. Behavioural toxicity of medicinal drugs: Practical consequences, incidence, management and avoidance
46. A comparative study of acute and subchronic effects of dothiepin, fluoxetine and placebo on psychomotor and actual driving performance
47. Effects of changes in brain 5-HT activity on indicators of cortical arousal
48. 2 receptor blocker
49. Mechanisms of drug-induced impairment: A dimensional approach
50. Effects of ritanserin and 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) in the murine elevated plus-maze test of anxiety: An ethnographological study
51. Effects of ethanol, diphenhydramine, and triazolam after a nap
52. Sleepiness and the reinforcing and subjective effects of methylphenidate
53. The effects of flurazepam, lorazepam, and triazolam on sleep and memory
54. Daytime sleepiness and alertness
55. Effects of triazolam at three phases of the menstrual cycle
56. Serotonergic antidepressants effects on vigilance and cognition
57. Effect of pharmacologic treatments on the sleep of depressed patients
58. Evaluation of first night effect using ambulatory monitoring and automatic sleep stage analysis
59. Sleep stability with home sleep recording and automatic sleep stage analysis
60. 2C receptors
61. The comparison of benzodiazepine derivatives and serotonergic agonists and antagonists in two animal models of anxiety
62. Driving and benzodiazepine use. Evidence that they do not mix
63. Therapeutic effects and effects on actual driving performance of chronically administered buspirone and diazepam in anxious outpatients
64. Acute and subchronic effects of nefazodone and imipramine on highway driving, cognitive functions, and daytime sleepiness in healthy adult and elderly subjects
65. The effects of treatment with buspirone, diazepam and lorazepam on driving performance in real traffic
66. A comparative study of on-the-road and simulated driving performance after nocturnal treatment with lormetazepam 1 mg and oxazepam 50 mg
67. Evaluation of gender difference in regional brain metabolic responses to lorazepam